Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Orphan Designation Requests To Get Slower Reviews

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.


Related Content

Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says
Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Woodcock's Legacy: CDER Organizational Improvements
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
'Cures' vs Funding: FDA Appropriations Bill Is Latest Battleground
Priority Review Vouchers Could Be Used Frequently Next Year
Targeted Therapies On FDA’s Orphan Designation Radar
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst